Literature DB >> 30359171

Expanding Therapeutic Opportunities for Hematopoietic Stem Cell Transplantation: T Cell Depletion as a Model for the Targeted Allograft.

Christina Cho1, Miguel-Angel Perales1.   

Abstract

Allogeneic hematopoietic cell transplantation is a fundamental part of the treatment of hematologic malignancies and marrow failure syndromes, but complications including graft-versus-host disease, prolonged immune deficiency and infection, and organ toxicities, as well as relapse, remain obstacles to improved overall survival. As the cellular characteristics of the allograft can exert significant impact on outcomes, the development of more strategically designed grafts represents a rich area for therapeutic intervention. We describe the use of ex vivo T cell-depleted grafts as a model for the targeted graft and review evolving knowledge and approaches for further refinement of allografts to improve patient outcomes.

Entities:  

Keywords:  T cell depletion; allogeneic hematopoietic cell transplantation; graft-versus-host disease; immune reconstitution

Mesh:

Year:  2018        PMID: 30359171     DOI: 10.1146/annurev-med-120617-041210

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  7 in total

1.  Human Herpesvirus 6 DNAemia Is Associated With Worse Survival After Ex Vivo T-Cell-Depleted Hematopoietic Cell Transplant.

Authors:  Yeon Joo Lee; Yiqi Su; Christina Cho; Roni Tamari; Miguel-Angel Perales; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  J Infect Dis       Date:  2022-02-01       Impact factor: 7.759

2.  Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm.

Authors:  Shuk Ying Chan; Rachel M Hughes; Kimberly Woo; Miguel-Angel Perales; Dionysios Neofytos; Genovefa Papanicolaou
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

3.  Adenovirus Viral Kinetics and Mortality in Ex Vivo T Cell-Depleted Hematopoietic Cell Transplant Recipients With Adenovirus Infection From a Single Center.

Authors:  Yeon Joo Lee; Jiaqi Fang; Phaedon D Zavras; Susan E Prockop; Farid Boulad; Roni Tamari; Miguel Angel Perales; Esperanza B Papadopoulos; Ann A Jakubowski; Sergio A Giralt; Genovefa A Papanicolaou
Journal:  J Infect Dis       Date:  2020-09-01       Impact factor: 5.226

Review 4.  Checkpoint inhibitors in AML: are we there yet?

Authors:  Arnab Ghosh; Pere Barba; Miguel-Angel Perales
Journal:  Br J Haematol       Date:  2019-12-06       Impact factor: 8.615

5.  Donor-CD4+ T Cells: A Trojan Horse for Human Herpes Virus-6 After Allogeneic Hematopoietic Cell Transplantation?

Authors:  Yeon Joo Lee; Yiqi Su; Christina Cho; Genovefa A Papanicolaou
Journal:  J Infect Dis       Date:  2022-02-01       Impact factor: 7.759

6.  Targeted in-vitro-stimulation reveals highly proliferative multi-virus-specific human central memory T cells as candidates for prophylactic T cell therapy.

Authors:  Benjamin Faist; Fabian Schlott; Christian Stemberger; Kevin M Dennehy; Angela Krackhardt; Mareike Verbeek; Götz U Grigoleit; Matthias Schiemann; Dieter Hoffmann; Andrea Dick; Klaus Martin; Martin Hildebrandt; Dirk H Busch; Michael Neuenhahn
Journal:  PLoS One       Date:  2019-09-30       Impact factor: 3.240

7.  Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation.

Authors:  Madhavi Lakkaraja; Michael Scordo; Audrey Mauguen; Christina Cho; Sean Devlin; Josel D Ruiz; Elizabeth Klein; Scott T Avecilla; Farid Boulad; Maria I Cancio; Kevin J Curran; Ann A Jakubowski; Nancy A Kernan; Andrew L Kung; Richard J O'Reilly; Esperanza B Papadopoulos; Susan Prockop; Ichelle van Roessel; Andromachi Scaradavou; Brian C Shaffer; Gunjan Shah; Barbara Spitzer; Roni Tamari; Sergio A Giralt; Miguel-Angel Perales; Jaap Jan Boelens
Journal:  Blood Adv       Date:  2022-02-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.